FDA Reverses Regulatory Stance and Agreement Details

Recently, the U.S. Food and Drug Administration (FDA) reversed its initial rejection of REGENXBIO's gene therapy, Navsunli (clemidsogene lanparvovec-sngl), for Hunter Syndrome, and has reached an agreement to expedite the approval process. Previously, the FDA had requested a placebo-controlled group or an expanded clinical trial in its February review, leading to the rejection of the Biologics License Application (BLA). However, through an appeal process, the FDA has agreed to allow the resubmission of the BLA based on existing clinical data. This decision is considered a prime example of regulatory flexibility, taking into account the clinical realities of rare genetic disease treatment. REGENXBIO plans to complete the resubmission of the BLA within the third quarter (3Q), following a Type A meeting scheduled for July.

Mechanism of Action and Neurological Effects of Navsunli

Navsunli is a one-time adeno-associated virus (AAV9) vector-based gene therapy designed to treat Hunter Syndrome (mucopolysaccharidosis type II, MPS II) by addressing the deficiency of iduronate-2-sulfatase (IDS) enzyme. This rare genetic disorder causes the abnormal accumulation of glycosaminoglycans (GAGs) in the central nervous system, leading to cognitive impairment and physical decline. Existing enzyme replacement therapy (ERT), administered intravenously, cannot effectively cross the blood-brain barrier (BBB) to prevent neurological damage in the brain. In contrast, Navsunli is directly administered into the cerebrospinal fluid (CSF), delivering the IDS gene directly to brain tissue, reducing GAG levels in the CSF, and demonstrating efficacy in inhibiting disease progression.

FDA's New Leadership and Regulatory Normalization

This reversal of the FDA's stance is part of a broader trend of regulatory easing, correcting the conservative decisions made during the tenures of former interim commissioner Marty Makary and former director Vinay Prasad. The previous leadership was criticized for imposing traditional placebo-controlled trials and stringent evaluation criteria even for rare diseases, which stifled industry development efforts. However, the new FDA leadership has emphasized ensuring the survival rights of rare disease patients and addressing unmet needs, leading to the renewed utilization of accelerated approval pathways. As a result, following uniQure and Replimune, REGENXBIO has also secured the opportunity to resubmit its marketing application without requiring additional clinical trials.

Hunter Syndrome Treatment Market and Competitive Landscape

The global market for Hunter Syndrome treatment is projected to grow from approximately $1.39 billion in 2025 to $2.55 billion in 2034, with an annual growth rate of 7%. Currently, the market is dominated by Takeda's Elaprase, but Denali Therapeutics recently received accelerated approval for Avlayah, which can alleviate cognitive symptoms, signaling increased competition. With REGENXBIO planning to resubmit the BLA for Navsunli in the third quarter, it has the potential to establish a competitive advantage as an innovative, one-time treatment that offers the prospect of a cure. On the day of the regulatory agreement announcement, REGENXBIO's stock price rose by as much as 17% during trading hours, demonstrating market expectations for its commercial potential.